Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TRN501 in Healthy Japanese Male Volunteers
NCT06453551Phase 1Completed
- Sponsor
- SNLD
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRN501 in Parkinson's disease (PD) (8 arms), sponsored by SNLD. Primary endpoints: Incidents of Treatment-Emergent Adverse Events at 4 weeks, Incidents of physical findings at 3 days and 5 more. Started May 2024; status: completed.
02
Drugs
TRN501
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06453551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453551.